Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 November 3, 2023 Editas Medicine Announces Third Quarter 2023 Results and Business Updates November 2, 2023 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar October 27, 2023 Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events October 16, 2023 Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease September 25, 2023 Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer September 25, 2023 Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer August 30, 2023 Editas Medicine Announces Upcoming Investor Events August 2, 2023 Editas Medicine Announces Second Quarter 2023 Results and Business Updates July 27, 2023 Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization July 26, 2023 Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
November 2, 2023 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
October 27, 2023 Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 16, 2023 Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
September 25, 2023 Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023 Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
July 27, 2023 Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 26, 2023 Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
